Getting Alzheimer’s treatment to those who need it poses particular challenges; Cytokinetics set to pitch its heart drug to physicians — and Big Pharma suitors

Taking stock of the drug industry, from the lab to the medicine chest

May 9, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Ben Margot/AP STAT+ | Getting Alzheimer's treatment to those who need it poses particular challenges Diagnosis, treatment, monitoring and access can pose problems for both patients and their doctors, experts said at a STAT virtual event Wednesday. By Matthew Herper STAT+ | Drug supplies for millions would be jeopardized by U.S. crackdown on China biopharma industry, trade group says The group says nearly 80% of the 124 companies that responded to its survey work with Chinese companies for some aspect of manufacturing and development. By John Wilkerson STAT+ | Cytokinetics set to pitch its heart drug to physicians — and Big Pharma suitors This week in biotechnology: Adam Feuerstein's subscriber-only newsletter digs into Cytokinetics, Vertex, and Bluebird. By Adam Feuerstein Wikimedia Commons Exact Sciences' stock tumbles amid worries cancer detection firm's growth may slow Will colon cancer screening revenue increase steeply enough to meet the cancer detection company's projections? By Jonathan Wosen STAT+ | Health care leaders plot how to expand diversity in clinical trials Milken Conference panel says outreach needed to build trust among communities with a history of being mistreated or exploited by the scientific community. By Annalisa Merelli

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser